Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19972610 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2GPR119LMNAMAPTTP53 | |
| SCHEMBL19980662 | 0.90 | SMN1; SMN2 (0.46) | SMN1; SMN2GPR119LMNAMAPTTP53 | |
| SCHEMBL29986162 | 0.90 | SMN1; SMN2 (0.46) | SMN1; SMN2GPR119LMNAMAPTTP53 | |
| SCHEMBL31001668 | 0.88 | SMN1; SMN2 (0.47) | SMN1; SMN2GPR119LMNAMAPTTP53 | |
| SCHEMBL19972493 | 0.88 | SMN1; SMN2 (0.47) | SMN1; SMN2GPR119LMNAMAPTTP53 | |
| SCHEMBL19972496 | 0.88 | SMN1; SMN2 (0.45) | SMN1; SMN2GPR119LMNAMAPTTP53 | |
| SCHEMBL30265803 | 0.88 | SMN1; SMN2 (0.45) | SMN1; SMN2GPR119LMNAMAPTTP53 | |
| SCHEMBL31068851 | 0.88 | SMN1; SMN2 (0.50) | SMN1; SMN2GPR119LMNAMAPTTP53 | |
| SCHEMBL19972501 | 0.87 | SMN1; SMN2 (0.47) | SMN1; SMN2GPR119LMNAMAPTTP53 | |
| SCHEMBL31001698 | 0.87 | SMN1; SMN2 (0.47) | SMN1; SMN2GPR119LMNAMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559487-B2 | Crosslinked optically active secondary amine derivative | Sumitomo Pharma Co., Ltd. (JP) | 2026-02-24 | — | — | US | disclosed |
| CN-118359610-A | MENIN-MLL interaction inhibitors | 生命医药有限责任公司 | 2024-07-19 | — | — | CN | disclosed |
| US-20240124447-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC (US) | 2024-04-18 | — | — | US | disclosed |
| EP-3512850-B1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS LLC (US) | 2023-04-12 | — | — | EP | disclosed |
| US-20220380365-A1 | CROSSLINKED OPTICALLY ACTIVE SECONDARY AMINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380365-A1 | CROSSLINKED OPTICALLY ACTIVE SECONDARY AMINE DERIVATIVE | MLLT3, MLLT1, MEN1 | SMN1; SMN2 2691/4885GPR119 3039/4885LMNA 576/4885 |
| US-12559487-B2 | Crosslinked optically active secondary amine derivative | MLLT3, MLLT1, FLI1 | SMN1; SMN2 2086/4885GPR119 2923/4885LMNA 836/4885 |
| US-20240124447-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | SMN1; SMN2 1680/4885GPR119 3311/4885LMNA 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.